The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Glycosylation of Recombinant Antibody Therapeutics
Abstract
The adaptive immune system has the capacity to produce antibodies with a virtually infinite repertoire of specificities. Recombinant antibodies specific for human targets are established in the clinic as therapeutics and represent a major new class of drug. Therapeutic efficacy depends on the formation of complexes with target molecules and subsequent activation of downstream biologic effector mechanisms that result in elimination of the target. The activation of effector mechanisms is dependent on structural characteristics of the antibody molecule that result from posttranslational modifications, in particular, glycosylation. The production of therapeutic antibody with a consistent human glycoform profile has been and remains a considerable challenge to the biopharmaceutical industry. Recent research has shown that individual glycoforms of antibody may provide optimal efficacy for selected outcomes. Thus a further challenge will be the production of a second generation of antibody therapeutics customized for their clinical indication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Malhotra, R., Wormald, M. R., Rudd, P. M., Fischer, P. B., Dwek, R. A., & Sim, R. B. (1995) · Nature Medicine · doi:10.1038/nm0395-237 · Cited by 786
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 719
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674
Self-citationCrystal structure of the complex of rat neonatal Fc receptor with Fc
Burmeister, W. P., Huber, A. H., & Bjorkman, P. J. (1994) · Nature · doi:10.1038/372379a0 · Cited by 431
Cited by
Post-translational modifications in the context of therapeutic proteins
Walsh, G., & Jefferis, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1252 · Cited by 1,005
Self-citationGlycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
“These effector ligands include three structurally homologous cellular Fc receptor types (FcγRI, FcγRII and FcγRIII), the C1q component of complement and the neonatal Fc receptor (FcRn”
BackgroundSelf-citationAntibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Pučić, M., Knežević, A., Vidič, J., Adamczyk, B., Novokmet, M., Polašek, O., Gornik, O., Šupraha-Goreta, S., Wormald, M. R., Redžić, I., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.010090 · Cited by 524
Mammalian cell protein expression for biopharmaceutical production
Zhu, J. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.08.022 · Cited by 491
Heterogeneity of Monoclonal Antibodies
Liu, H., Gaza-Bulseco, G., Faldu, D., Chumsae, C., & Sun, J. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21180 · Cited by 481
Glycan labeling strategies and their use in identification and quantification
Ruhaak, L. R., Zauner, G., Huhn, C., Bruggink, C., Deelder, A. M., & Wuhrer, M. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3532-z · Cited by 479
Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr027 · Cited by 467
Glycosylation of Therapeutic Proteins: An Effective Strategy to Optimize Efficacy
Solá, R. J., & Griebenow, K. (2010) · BioDrugs · doi:10.2165/11530550-000000000-00000 · Cited by 440
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
van Schouwenburg, P. A., Rispens, T., & Wolbink, G. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 438
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
Immunoglobulin G glycosylation in aging and diseases
Gudelj, I., Lauc, G., & Pezer, M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.009 · Cited by 408
Wada, Y., Azadi, P., Costello, C. E., Dell, A., Dwek, R. A., Geyer, H., Geyer, R., Kakehi, K., Karlsson, N. G., Kato, K., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl086 · Cited by 400
Scallon, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N., & Raju, T. S. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.09.005 · Cited by 396
Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro
Hodoniczky, J., Zheng, Y. Z., & James, D. C. (2005) · Biotechnology Progress · doi:10.1021/bp050228w · Cited by 393
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
McCombs, J. R., & Owen, S. C. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9710-8 · Cited by 393
Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372
Lauc, G., Huffman, J. E., Pučić, M., Zgaga, L., Adamczyk, B., Mužinić, A., Novokmet, M., Polašek, O., Gornik, O., Krištić, J., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003225 · Cited by 361
Recent advances in the construction of antibody–drug conjugates
Chudasama, V., Maruani, A., & Caddick, S. (2016) · Nature Chemistry · doi:10.1038/nchem.2415 · Cited by 352
Formulation and delivery issues for monoclonal antibody therapeutics
Daugherty, A. L., & Mrsny, R. J. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.03.011 · Cited by 351
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Mass spectrometry for structural characterization of therapeutic antibodies
Zhang, Z., Pan, H., & Chen, X. (2009) · Mass Spectrometry Reviews · doi:10.1002/mas.20190 · Cited by 316
Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions
Huang, W., Giddens, J., Fan, S.-Q., Toonstra, C., & Wang, L.-X. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3051266 · Cited by 308
Huhn, C., Selman, M. H. J., Ruhaak, L. R., Deelder, A. M., & Wuhrer, M. (2009) · PROTEOMICS · doi:10.1002/pmic.200800715 · Cited by 301
Advances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
Self-citationQian, J., Liu, T., Yang, L., Daus, A., Crowley, R., & Zhou, Q. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.01.023 · Cited by 291
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Developability Assessment During the Selection of Novel Therapeutic Antibodies
Jarasch, A., Koll, H., Regula, J. T., Bader, M., Papadimitriou, A., & Kettenberger, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24430 · Cited by 242
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234
Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose
Gramer, M. J., Eckblad, J. J., Donahue, R., Brown, J., Shultz, C., Vickerman, K., Priem, P., van den Bremer, E. T. J., Gerritsen, J., & van Berkel, P. H. C. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23075 · Cited by 193
Current and future issues in the manufacturing and development of monoclonal antibodies
Kozlowski, S., & Swann, P. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.05.002 · Cited by 170
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria
Robinson, M.-P., Ke, N., Lobstein, J., Peterson, C., Szkodny, A., Mansell, T. J., Tuckey, C., Riggs, P. D., Colussi, P. A., Noren, C. J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9072 · Cited by 131
Bush, D. R., Zang, L., Belov, A. M., Ivanov, A. R., & Karger, B. L. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b03218 · Cited by 92
Gahoual, R., Burr, A., Busnel, J.-M., Kuhn, L., Hammann, P., Beck, A., François, Y.-N., & Leize-Wagner, E. (2013) · mAbs · doi:10.4161/mabs.23995 · Cited by 90
Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid
Yehuda, S., & Padler-Karavani, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00021 · Cited by 71
Onitsuka, M., Kim, W.-D., Ozaki, H., Kawaguchi, A., Honda, K., Kajiura, H., Fujiyama, K., Asano, R., Kumagai, I., Ohtake, H., et al. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3814-1 · Cited by 48
The Pathogenicity of Anti-β 2GP1-IgG Autoantibodies Depends on Fc Glycosylation
Fickentscher, C., Magorivska, I., Janko, C., Biermann, M., Bilyy, R., Nalli, C., Tincani, A., Medeghini, V., Meini, A., Nimmerjahn, F., et al. (2015) · Journal of Immunology Research · doi:10.1155/2015/638129 · Cited by 37
Fan, L., Frye, C. C., & Racher, A. J. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.56 · Cited by 35
Metadata
- Authors
- Jefferis, R.
- Venue
- Biotechnology Progress
- Publisher
- Wiley
- Published
- 2008-09-05
- Volume
- 21
- Issue
- 1
- Pages
- 11-16
- ISSN
- 1520-6033 (ISSN-L)
- 8756-7938
- OpenAlex
- W2030932286
- Cited by
- 526
- References
- 40
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.